文献速递肿瘤 PET/CT

[68Ga]Ga-FAPI-04 PET/CT 在上皮性卵巢癌评估中的应用:与[18F]F-FDG PET/CT 的比较

[68Ga]Ga-FAPI-04 PET/CT in the evaluation of epithelial ovarian cancer: comparison with [18F]F-FDG PET/CT.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-08-01

纳入49例组织学证实为原发性或复发性上皮性卵巢癌(EOC)的患者,对比[68Ga]Ga-FAPI-04与[18F]F-FDG PET/CT在检测原发或复发肿瘤及转移灶中的效能。[68Ga]Ga-FAPI-04 PET/CT在腹膜转移、腹膜后及膈上淋巴结转移的检出率更高,以手术病理为金标准时敏感性更高,并导致部分患者分期升级和治疗管理改变。

要点

  • 49例EOC患者中28例原发、21例复发,均行两种PET/CT显像对比。
  • [68Ga]Ga-FAPI-04对腹膜转移检出率96.8%高于[18F]F-FDG的83.0%(p<0.001)。
  • 以手术病理为金标准,FAPI-04对腹膜转移敏感性97.5%高于FDG的75.9%(p<0.001)。

核心结论

  • [68Ga]Ga-FAPI-04 PET/CT在淋巴结和腹膜转移的检测与诊断中敏感性高于[18F]F-FDG PET/CT,提示在EOC患者术前分期方面具有优势,从而改善治疗决策。

研究设计与样本

  • 研究纳入49例经组织学证实的原发性或复发性EOC患者,中位年龄57岁(IQR 51–66岁)。
  • 所有参与者均接受[18F]F-FDG和[68Ga]Ga-FAPI-04 PET/CT显像检查。
  • 比较两种示踪剂的检出率、诊断准确率、半定量参数、肿瘤分期及临床管理,并以手术病理评估诊断效能。
  • 同时评估影像学腹膜癌指数(PCI)、手术PCI及肿瘤标志物(CA125、HE4)在腹膜转移方面的差异。
  • 试验注册号NCT05034146,注册日期2021年2月23日。

主要发现

  • 49例患者中28例为原发性EOC,21例为复发性EOC。
  • [68Ga]Ga-FAPI-04 PET/CT在腹膜转移检出率上为96.8% vs [18F]F-FDG的83.0%(p<0.001)。
  • [68Ga]Ga-FAPI-04 PET/CT在腹膜后淋巴结转移检出率上为99.5% vs [18F]F-FDG的91.4%(p<0.001)。
  • [68Ga]Ga-FAPI-04 PET/CT在膈上淋巴结转移检出率上为100% vs [18F]F-FDG的80.4%(p<0.001)。
  • [68Ga]Ga-FAPI-04较[18F]F-FDG显示更高的SUVmax:腹膜转移17.31 vs 13.68(p=0.026),腹膜后淋巴结转移8.72 vs 6.56(p<0.001),膈上淋巴结转移6.39 vs 4.20(p<0.001)。

关键数值与推荐

  • 以手术病理为金标准,[68Ga]Ga-FAPI-04 PET/CT检测转移性淋巴结的敏感性为80.6% vs [18F]F-FDG的61.3%(p=0.031)。
  • 以手术病理为金标准,[68Ga]Ga-FAPI-04 PET/CT检测腹膜转移的敏感性为97.5% vs [18F]F-FDG的75.9%(p<0.001)。
  • [68Ga]Ga-FAPI-04 PET/CT较[18F]F-FDG PET/CT使14.3%的初治参与者和33.3%的复发参与者分期升级。
  • [68Ga]Ga-FAPI-04 PET/CT较[18F]F-FDG PET/CT分别导致10.7%的初治患者和19.0%的复发患者治疗管理改变。
  • 中位PCIFAPI评分显著高于PCIFDG(15 vs 11;p<0.001),且与CA125、HE4水平及手术PCI正相关。

临床怎么用

  • 原文结论指出[68Ga]Ga-FAPI-04 PET/CT在EOC患者术前分期方面提示具有优势,从而改善治疗决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare the efficacy of [68Ga]Ga-FAPI-04 PET/CT in primary or recurrent tumors and metastatic lesions of epithelial ovarian cancer (EOC) with that of fluorine-18 fluorodeoxyglucose ([18F]F-FDG) PET/CT. METHODS: Forty-nine patients (median age, 57 years; IQR, 51-66 years) with histologically proven primary or relapsed EOC were enrolled. Participants underwent [18F]F-FDG and [68Ga]Ga-FAPI-04 PET/CT. The detection rate, diagnostic accuracy, semiquantitative parameters, tumor staging, and clinical management of the tracers were compared. The diagnostic performance of [18F]F-FDG and [68Ga]Ga-FAPI-04 PET/CT was evaluated and compared using surgical pathology. Differences between methods regarding the peritoneal cancer index (PCI) using preoperative imaging, surgical PCI, and tumor markers (CA125, HE4) were also assessed regarding peritoneal metastases. RESULTS: Among the 49 patients, 28 had primary EOC; 21 had relapsed EOC. [68Ga]Ga-FAPI-04 PET/CT outperformed [18F]F-FDG PET/CT in detecting peritoneal metastases (96.8% vs. 83.0%; p < 0.001), retroperitoneal (99.5% vs. 91.4%; p < 0.001), and supradiaphragmatic lymph node metastases (100% vs. 80.4%; p < 0.001). Compared with [18F]F-FDG, [68Ga]Ga-FAPI-04 showed higher SUVmax for peritoneal metastases (17.31 vs. 13.68; p = 0.026) and retroperitoneal (8.72 vs. 6.56; p < 0.001) and supradiaphragmatic lymph node metastases (6.39 vs. 4.20; p < 0.001). Moreover, [68Ga]Ga-FAPI-04 PET/CT showed higher sensitivity compared with [18F]F-FDG PET/CT for detecting metastatic lymph nodes (80.6% vs. 61.3%; p = 0.031) and peritoneal metastases (97.5% vs. 75.9%; p < 0.001), using surgical pathology as the gold standard. Compared with [18F]F-FDG PET/CT, [68Ga]Ga-FAPI-04 PET/CT led to an upgrade in 14.3% and 33.3% of treatment-naive and relapse participants, resulting in management changes in 10.7% and 19.0% of the patients, respectively. The median PCIFAPI scores were significantly higher than PCIFDG (15 vs. 11; p < 0.001) and positively correlated with CA125 and HE4 levels and surgical PCI. CONCLUSION: [68Ga]Ga-FAPI-04 PET/CT achieved higher sensitivity than [18F]F-FDG PET/CT in the detection and diagnosis of lymph node and peritoneal metastases, suggesting advantages regarding the preoperative staging of patients with EOC and, thereby, improving treatment decision-making. TRIAL REGISTRATION: NCT05034146. Registered February 23, 2021.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Chen J, Xu K, Li C, et al. [68Ga]Ga-FAPI-04 PET/CT in the evaluation of epithelial ovarian cancer: comparison with [18F]F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2023. PMID: 37526694. doi:10.1007/s00259-023-06369-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。